ArticleScientific reports2025
An ovalbumin-based hydrogel loaded with dendrobium polysaccharide for promoting wound healing while reducing inflammations.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The challenges associated with wound healing are multifaceted, encompassing factors such as susceptibility to infection, inadequate blood supply to injured tissues, and the retention of foreign bodies. Development of a wound repair product that can effectively overcome the aforementioned issues at a relatively low cost would better meet the needs of patients. Consequently, this research aimed to develop a low-cost hydrogel with a simple preparation process to accelerate wound healing and reduce the risk of infection. Given their abundance and low cost, ovalbumin (OVA), dendrobium polysaccharide (DOPs), and erythromycin (EM) were selected as the primary components for constructing the composite hydrogel. In vitro experiments revealed that a solution containing 0.4 g/mL OVA, 50 mg/mL DOPs, and 100 µg/mL EM could effectively form a composite hydrogel when incubated in a warm bath at 53°C for 40 min. The resulting OVA/EM/DOPs hydrogel demonstrated exceptional properties, including strong adhesion, regenerative capacity, water retention, hydrophilicity, non-hemolytic behavior, and antimicrobial activity. Cellular assays further confirmed that the OVA/EM/DOPs hydrogel exhibited low cytotoxicity, excellent biocompatibility, and the ability to enhance scratch closure in L929 cells. In vivo wound healing experiments demonstrated that the composite hydrogel significantly accelerated wound repair by upregulating the expression of CD31 and VEGF while reducing levels of IL-10 and TNF-α. Both in vitro and in vivo findings consistently supported the hydrogel's efficacy in promoting wound healing and mitigating inflammation, highlighting its considerable potential for clinical wound management. The research not only offers a promising, low-cost option for wound repair but also broadens the potential applications of DOPs. Furthermore, the successful design of this composite hydrogel provides a novel framework for developing other simple and economical hydrogel-based materials, paving the way for innovative approaches in wound care and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.